By Associate Professor Megan Amanda Crumbaker

Journal articles

Mersiades A; Crumbaker M; Gao B; Nagrial A; Hui R, 2017, 'P3.02c-033 Patterns of Progression and Management of Acquired Resistance to Anti-PD-1 Antibodies in Advanced Non-Small Cell Lung Cancer', Journal of Thoracic Oncology, 12, pp. S1293 - S1293, http://dx.doi.org/10.1016/j.jtho.2016.11.1828

Crumbaker M; Carlino M; Hui R; Mersiades A; Gurney H; Todd J; Gao B; Nagrial A, 2016, '471P Baseline full blood count parameters as predictors of response to PD-1 inhibition in advanced NSCLC', Annals of Oncology, 27, pp. ix151 - ix151, http://dx.doi.org/10.1016/s0923-7534(21)00629-3

Crumbaker M; Carlino M; Hui R; Mersiades A; Gurney H; Todd J; Gao B; Nagrial A, 2016, '471P Baseline full blood count parameters as predictors of response to PD-1 inhibition in advanced NSCLC', Annals of Oncology, 27, http://dx.doi.org/10.1093/annonc/mdw594.035

Chan D; McLachlan JM; Crumbaker M; Marx GM, 2015, 'Pretreatment neutrophil/lymphocyte ratio (NLR) prior to steroids as a prognostic factor in metastatic castrate refractory prostate cancer (mCRPC) patients treated with taxanes.', JOURNAL OF CLINICAL ONCOLOGY, 33, http://dx.doi.org/10.1200/jco.2015.33.7_suppl.273

McLachlan JM; Chan DL; Crumbaker MA; Marx GM, 2015, 'Neutrophil-lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancer', Cancer Treatment Communications, 4, pp. 81 - 85, http://dx.doi.org/10.1016/j.ctrc.2015.06.001

Conference Papers

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302400&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900189&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Crumbaker M; Joshua AM; Epstein R; Emmett L, 2018, 'A phase I study of Lu-177-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.TPS5088

Arasaratnam M; Balakrishnar B; Crumbaker M; Turner S; Hayden AJ; Brooks A; Patel MI; Gurney H, 2018, 'Patterns of Care and Outcome of Germ Cell Tumours (GCT) in an Australian High-Volume Centre', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 28 - 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000437670700015&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Itchins M; Sinn K; Chan D; Crumbaker M; Gill A; Clarke S; Pavlakis N, 2015, 'ALK TRANSLOCATED NON-SMALL CELL LUNG CANCER: EXPERIENCE FROM AN AUSTRALIAN METROPOLITAN TERTIARY REFERRAL CENTRE', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 174 - 175, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800315&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Kumar AR; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of Lu-177-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301433&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5027 - 5027, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5027

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of Lu-177-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301444&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Ravi Kumar A; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5017 - 5017, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5017

Emmett L; Subramaniam S; Martin AJ; Zhang AY; Yip S; Crumbaker M; Rana N; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; Weickhardt AJ; Goh JC; Ng S; Voskoboynik M; McJannett MM; Stockler MR; Davis ID, 2022, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.TPS205

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Niman R; Wilson P; Sharma S; Ayers M; Eu P; Stockler MR; Martin AJ; Joshua AM; Emmett L, 2022, 'Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 1(77)LuPSMA-617 and NOX66 (LuPIN).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.166

Sandhu SK; Joshua AM; Emmett L; Spain L; Horvath LG; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Kumar AR; Alipour R; Akhurst T; Kong G; Davis ID; Williams S; Hicks R; Hofman M, 2021, 'PRINCE: Interim analysis of the phase Ib study of Lu-177-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S626 - S627, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1090

Lau B; Crumbaker M; Yam AOW; Marastoni S; Luckhurst M; O'Grady A; Wouters B; Joshua AM, 2021, 'A phase I/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): Dose escalation results.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.114

Emmett L; Subramaniam S; Zhang AY; Martin AJ; Yip S; Crumbaker M; Rana N; Ford K; Langford A; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; McJannett MM; Stockler MR; Davis ID, 2021, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS177

Pathmanandavel S; Crumbaker M; Yam AOW; Rofe C; Ho B; Chan WL; Sharma S; Hickey AJ; Kongrak K; Ratnayake L; Kwan EM; Azad A; Eu P; Nguyen A; Joshua AM; Emmett L, 2021, 'Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.103

Ardolino L; Tang R; Pathmanandavel S; Crumbaker M; Joshua A; Emmett L, 2019, 'Lu-177-PSMA-617 as monotherapy or in combination with NOX66 for the treatment of men with late-stage metastatic castrate resistant prostate cancer (mCRPC): An exploratory analysis', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 115 - 115, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400147&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Crumbaker M; Nguyen A; Ho B; Yin C; Isheish N; Azad A; Violet J; Sharma S; Joshua A, 2019, 'Interim results of a Phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and NOX66 in men with mCRPC post androgen signalling inhibition and 2 lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CA, Anaheim, Vol. 60, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CA, Anaheim, 22 June 2019 - 25 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473116800464&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Chen J; Joshua AM; Denmeade SR; Antonarakis ES; Crumbaker M, 2019, 'High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.TPS5095

Back to profile page